Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cyclacel Pharmaceuticals

9.24
+1.4118.01%
Volume:112.92K
Turnover:1.40M
Market Cap:104.01M
PE:-1.48
High:17.00
Open:7.82
Low:7.41
Close:7.83
Loading ...

Company Profile

Company Name:
Cyclacel Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
1996
Employees:
12
Office Location:
200 Connell Drive,Suite 1500,Berkeley Heights,New Jersey,United States
Zip Code:
07922
Fax:
866 271 3466
Introduction:
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Directors

Name
Position
Christopher S. Henney
Vice Chairman and Director
David U'Prichard
Chairman of the Board of Director and Director
Spiro Rombotis
President and Chief Executive Officer and Director
Paul McBarron
Executive Vice President-Finance, Chief Financial Officer, Chief Operating Officer and Secretary,Director
Gregory T. Hradsky
Director
John Banham
Director
Lloyd Sems
Director
Robert Spiegel
Director
Samuel L. Barker
Director

Shareholders

Name
Position
Spiro Rombotis
President and Chief Executive Officer and Director
Paul McBarron
Executive Vice President-Finance, Chief Financial Officer, Chief Operating Officer and Secretary,Director
Judy Chiao
Vice President, Clinical Development and Regulatory Affairs